Survival, local control, and health‐related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study
Background The treatment of oligometastatic (≤5 metastases) spinal disease has trended toward ablative therapies, yet to the authors’ knowledge little is known regarding the prognosis of patients presenting with oligometastatic spinal disease and the value of this approach. The objective of the curr...
Gespeichert in:
| Veröffentlicht in: | Cancer 2019-03, Vol.125 (5), p.770-778 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 778 |
|---|---|
| container_issue | 5 |
| container_start_page | 770 |
| container_title | Cancer |
| container_volume | 125 |
| creator | Barzilai, Ori Versteeg, Anne L. Sahgal, Arjun Rhines, Laurence D. Bilsky, Mark H. Sciubba, Daniel M. Schuster, James M. Weber, Michael H. Pal Varga, Peter Boriani, Stefano Bettegowda, Chetan Fehlings, Michael G. Yamada, Yoshiya Clarke, Michelle J. Arnold, Paul M. Gokaslan, Ziya L. Fisher, Charles G. Laufer, Ilya the AO Spine Knowledge Forum Tumor |
| description | Background
The treatment of oligometastatic (≤5 metastases) spinal disease has trended toward ablative therapies, yet to the authors’ knowledge little is known regarding the prognosis of patients presenting with oligometastatic spinal disease and the value of this approach. The objective of the current study was to compare the survival and clinical outcomes of patients with cancer with oligometastatic spinal disease with those of patients with polymetastatic (>5 metastases) disease.
Methods
The current study was an international, multicenter, prospective study. Patients who were admitted to a participating spine center with a diagnosis of spinal metastases and who underwent surgical intervention and/or radiotherapy between August 2013 and May 2017 were included. Data collected included demographics, overall survival, local control, and treatment information including surgical, radiotherapy, and systemic therapy details. Health‐related quality of life (HRQOL) measures included the EuroQOL 5 dimensions 3‐level questionnaire (EQ‐5D‐3L), the 36‐Item Short Form Health Survey (SF‐36v2), and the Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ).
Results
Of the 393 patients included in the current study, 215 presented with oligometastatic disease and 178 presented with polymetastatic disease. A significant survival advantage of 90.1% versus 77.3% at 3 months and 77.0% versus 65.1% at 6 months from the time of treatment was found for patients presenting with oligometastatic disease compared with those with polymetastatic disease. It is important to note that both groups experienced significant improvements in multiple HRQOL measures at 6 months after treatment, with no differences in these outcome measures noted between the 2 groups.
Conclusions
The treatment of oligometastatic disease appears to offer a significant survival advantage compared with polymetastatic disease, regardless of treatment choice. HRQOL measures were found to improve in both groups, demonstrating a palliative benefit for all treated patients.
There appears to be a significant survival advantage for patients presenting with oligometastatic disease compared with those with polymetastatic disease at the time of the initial treatment of spinal metastases regardless of the treatment method used. In the current study, both groups are reported to experience significant improvements in multiple measures of health‐related quality of life at 6 months. |
| doi_str_mv | 10.1002/cncr.31870 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8020734</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2182192019</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4480-cfc36731370f13f84f9c4d940ff3a8fe779d75672eb805679fd055806bcef5a63</originalsourceid><addsrcrecordid>eNp9kd1qFDEUx4Modq3e-AAS8E469WSSmWS8EMriFxQFP8C7kM0k3ZTMZJtktsxdH6Hv4Jv5JGa7tdQbrw7n5MfvnPBH6DmBYwJQv9ajjseUCA4P0IJAxysgrH6IFgAgqobRnwfoSUrnpeV1Qx-jAwpMdC1lC_Tr2xS3bqv8EfZBK491GHMMpVVjj9dG-bz-fXUdjVfZ9PhiUt7lGQeLvbMGuxFvVHZmzAlfurzGwbuzMJisUi5zfWPZBD_fG6WNG8uiPA0hpjf4BA-TL_PiMPGoGEsZCxh2UMpTPz9Fj6zyyTy7rYfox_t335cfq9MvHz4tT04rzZiASltNW04J5WAJtYLZTrO-Y2AtVcIazrueNy2vzUpAqZ3toWkEtCttbKNaeoje7r2baTWYfndRVF5uohtUnGVQTv77Mrq1PAtbKaAGTlkRvLwVxHAxmZTleZjKZ3ySNRE16WogXaFe7SkdQ0rR2LsNBOQuULkLVN4EWuAX92-6Q_8mWACyBy6dN_N_VHL5efl1L_0DU_Kxtg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2182192019</pqid></control><display><type>article</type><title>Survival, local control, and health‐related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>Alma/SFX Local Collection</source><creator>Barzilai, Ori ; Versteeg, Anne L. ; Sahgal, Arjun ; Rhines, Laurence D. ; Bilsky, Mark H. ; Sciubba, Daniel M. ; Schuster, James M. ; Weber, Michael H. ; Pal Varga, Peter ; Boriani, Stefano ; Bettegowda, Chetan ; Fehlings, Michael G. ; Yamada, Yoshiya ; Clarke, Michelle J. ; Arnold, Paul M. ; Gokaslan, Ziya L. ; Fisher, Charles G. ; Laufer, Ilya ; the AO Spine Knowledge Forum Tumor</creator><creatorcontrib>Barzilai, Ori ; Versteeg, Anne L. ; Sahgal, Arjun ; Rhines, Laurence D. ; Bilsky, Mark H. ; Sciubba, Daniel M. ; Schuster, James M. ; Weber, Michael H. ; Pal Varga, Peter ; Boriani, Stefano ; Bettegowda, Chetan ; Fehlings, Michael G. ; Yamada, Yoshiya ; Clarke, Michelle J. ; Arnold, Paul M. ; Gokaslan, Ziya L. ; Fisher, Charles G. ; Laufer, Ilya ; the AO Spine Knowledge Forum Tumor</creatorcontrib><description>Background
The treatment of oligometastatic (≤5 metastases) spinal disease has trended toward ablative therapies, yet to the authors’ knowledge little is known regarding the prognosis of patients presenting with oligometastatic spinal disease and the value of this approach. The objective of the current study was to compare the survival and clinical outcomes of patients with cancer with oligometastatic spinal disease with those of patients with polymetastatic (>5 metastases) disease.
Methods
The current study was an international, multicenter, prospective study. Patients who were admitted to a participating spine center with a diagnosis of spinal metastases and who underwent surgical intervention and/or radiotherapy between August 2013 and May 2017 were included. Data collected included demographics, overall survival, local control, and treatment information including surgical, radiotherapy, and systemic therapy details. Health‐related quality of life (HRQOL) measures included the EuroQOL 5 dimensions 3‐level questionnaire (EQ‐5D‐3L), the 36‐Item Short Form Health Survey (SF‐36v2), and the Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ).
Results
Of the 393 patients included in the current study, 215 presented with oligometastatic disease and 178 presented with polymetastatic disease. A significant survival advantage of 90.1% versus 77.3% at 3 months and 77.0% versus 65.1% at 6 months from the time of treatment was found for patients presenting with oligometastatic disease compared with those with polymetastatic disease. It is important to note that both groups experienced significant improvements in multiple HRQOL measures at 6 months after treatment, with no differences in these outcome measures noted between the 2 groups.
Conclusions
The treatment of oligometastatic disease appears to offer a significant survival advantage compared with polymetastatic disease, regardless of treatment choice. HRQOL measures were found to improve in both groups, demonstrating a palliative benefit for all treated patients.
There appears to be a significant survival advantage for patients presenting with oligometastatic disease compared with those with polymetastatic disease at the time of the initial treatment of spinal metastases regardless of the treatment method used. In the current study, both groups are reported to experience significant improvements in multiple measures of health‐related quality of life at 6 months.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.31870</identifier><identifier>PMID: 30489634</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Ablation ; Aged ; Bone cancer ; Cancer ; Demographics ; Demography ; Female ; Health ; Health services ; health‐related quality of life (HRQOL) ; Humans ; International Cooperation ; Male ; Medical prognosis ; Medical treatment ; Metastases ; Metastasis ; Middle Aged ; Neoplasm Metastasis ; oligometastases ; Oncology ; Orthopedic Procedures ; Patients ; polymetastases ; Prognosis ; Prospective Studies ; Quality of life ; Quality of Life - psychology ; Questionnaires ; Radiation therapy ; Radiotherapy ; Spinal cancer ; Spinal Neoplasms - psychology ; Spinal Neoplasms - secondary ; Spinal Neoplasms - therapy ; Spine ; Surgery ; Survival ; Survival Analysis ; Treatment Outcome ; tumor ; Tumors</subject><ispartof>Cancer, 2019-03, Vol.125 (5), p.770-778</ispartof><rights>2018 American Cancer Society</rights><rights>2018 American Cancer Society.</rights><rights>2019 American Cancer Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4480-cfc36731370f13f84f9c4d940ff3a8fe779d75672eb805679fd055806bcef5a63</citedby><cites>FETCH-LOGICAL-c4480-cfc36731370f13f84f9c4d940ff3a8fe779d75672eb805679fd055806bcef5a63</cites><orcidid>0000-0002-4037-8716</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.31870$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.31870$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,778,782,883,1414,1430,27907,27908,45557,45558,46392,46816</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30489634$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barzilai, Ori</creatorcontrib><creatorcontrib>Versteeg, Anne L.</creatorcontrib><creatorcontrib>Sahgal, Arjun</creatorcontrib><creatorcontrib>Rhines, Laurence D.</creatorcontrib><creatorcontrib>Bilsky, Mark H.</creatorcontrib><creatorcontrib>Sciubba, Daniel M.</creatorcontrib><creatorcontrib>Schuster, James M.</creatorcontrib><creatorcontrib>Weber, Michael H.</creatorcontrib><creatorcontrib>Pal Varga, Peter</creatorcontrib><creatorcontrib>Boriani, Stefano</creatorcontrib><creatorcontrib>Bettegowda, Chetan</creatorcontrib><creatorcontrib>Fehlings, Michael G.</creatorcontrib><creatorcontrib>Yamada, Yoshiya</creatorcontrib><creatorcontrib>Clarke, Michelle J.</creatorcontrib><creatorcontrib>Arnold, Paul M.</creatorcontrib><creatorcontrib>Gokaslan, Ziya L.</creatorcontrib><creatorcontrib>Fisher, Charles G.</creatorcontrib><creatorcontrib>Laufer, Ilya</creatorcontrib><creatorcontrib>the AO Spine Knowledge Forum Tumor</creatorcontrib><title>Survival, local control, and health‐related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Background
The treatment of oligometastatic (≤5 metastases) spinal disease has trended toward ablative therapies, yet to the authors’ knowledge little is known regarding the prognosis of patients presenting with oligometastatic spinal disease and the value of this approach. The objective of the current study was to compare the survival and clinical outcomes of patients with cancer with oligometastatic spinal disease with those of patients with polymetastatic (>5 metastases) disease.
Methods
The current study was an international, multicenter, prospective study. Patients who were admitted to a participating spine center with a diagnosis of spinal metastases and who underwent surgical intervention and/or radiotherapy between August 2013 and May 2017 were included. Data collected included demographics, overall survival, local control, and treatment information including surgical, radiotherapy, and systemic therapy details. Health‐related quality of life (HRQOL) measures included the EuroQOL 5 dimensions 3‐level questionnaire (EQ‐5D‐3L), the 36‐Item Short Form Health Survey (SF‐36v2), and the Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ).
Results
Of the 393 patients included in the current study, 215 presented with oligometastatic disease and 178 presented with polymetastatic disease. A significant survival advantage of 90.1% versus 77.3% at 3 months and 77.0% versus 65.1% at 6 months from the time of treatment was found for patients presenting with oligometastatic disease compared with those with polymetastatic disease. It is important to note that both groups experienced significant improvements in multiple HRQOL measures at 6 months after treatment, with no differences in these outcome measures noted between the 2 groups.
Conclusions
The treatment of oligometastatic disease appears to offer a significant survival advantage compared with polymetastatic disease, regardless of treatment choice. HRQOL measures were found to improve in both groups, demonstrating a palliative benefit for all treated patients.
There appears to be a significant survival advantage for patients presenting with oligometastatic disease compared with those with polymetastatic disease at the time of the initial treatment of spinal metastases regardless of the treatment method used. In the current study, both groups are reported to experience significant improvements in multiple measures of health‐related quality of life at 6 months.</description><subject>Ablation</subject><subject>Aged</subject><subject>Bone cancer</subject><subject>Cancer</subject><subject>Demographics</subject><subject>Demography</subject><subject>Female</subject><subject>Health</subject><subject>Health services</subject><subject>health‐related quality of life (HRQOL)</subject><subject>Humans</subject><subject>International Cooperation</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical treatment</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>oligometastases</subject><subject>Oncology</subject><subject>Orthopedic Procedures</subject><subject>Patients</subject><subject>polymetastases</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Quality of life</subject><subject>Quality of Life - psychology</subject><subject>Questionnaires</subject><subject>Radiation therapy</subject><subject>Radiotherapy</subject><subject>Spinal cancer</subject><subject>Spinal Neoplasms - psychology</subject><subject>Spinal Neoplasms - secondary</subject><subject>Spinal Neoplasms - therapy</subject><subject>Spine</subject><subject>Surgery</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>tumor</subject><subject>Tumors</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kd1qFDEUx4Modq3e-AAS8E469WSSmWS8EMriFxQFP8C7kM0k3ZTMZJtktsxdH6Hv4Jv5JGa7tdQbrw7n5MfvnPBH6DmBYwJQv9ajjseUCA4P0IJAxysgrH6IFgAgqobRnwfoSUrnpeV1Qx-jAwpMdC1lC_Tr2xS3bqv8EfZBK491GHMMpVVjj9dG-bz-fXUdjVfZ9PhiUt7lGQeLvbMGuxFvVHZmzAlfurzGwbuzMJisUi5zfWPZBD_fG6WNG8uiPA0hpjf4BA-TL_PiMPGoGEsZCxh2UMpTPz9Fj6zyyTy7rYfox_t335cfq9MvHz4tT04rzZiASltNW04J5WAJtYLZTrO-Y2AtVcIazrueNy2vzUpAqZ3toWkEtCttbKNaeoje7r2baTWYfndRVF5uohtUnGVQTv77Mrq1PAtbKaAGTlkRvLwVxHAxmZTleZjKZ3ySNRE16WogXaFe7SkdQ0rR2LsNBOQuULkLVN4EWuAX92-6Q_8mWACyBy6dN_N_VHL5efl1L_0DU_Kxtg</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Barzilai, Ori</creator><creator>Versteeg, Anne L.</creator><creator>Sahgal, Arjun</creator><creator>Rhines, Laurence D.</creator><creator>Bilsky, Mark H.</creator><creator>Sciubba, Daniel M.</creator><creator>Schuster, James M.</creator><creator>Weber, Michael H.</creator><creator>Pal Varga, Peter</creator><creator>Boriani, Stefano</creator><creator>Bettegowda, Chetan</creator><creator>Fehlings, Michael G.</creator><creator>Yamada, Yoshiya</creator><creator>Clarke, Michelle J.</creator><creator>Arnold, Paul M.</creator><creator>Gokaslan, Ziya L.</creator><creator>Fisher, Charles G.</creator><creator>Laufer, Ilya</creator><creator>the AO Spine Knowledge Forum Tumor</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4037-8716</orcidid></search><sort><creationdate>20190301</creationdate><title>Survival, local control, and health‐related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study</title><author>Barzilai, Ori ; Versteeg, Anne L. ; Sahgal, Arjun ; Rhines, Laurence D. ; Bilsky, Mark H. ; Sciubba, Daniel M. ; Schuster, James M. ; Weber, Michael H. ; Pal Varga, Peter ; Boriani, Stefano ; Bettegowda, Chetan ; Fehlings, Michael G. ; Yamada, Yoshiya ; Clarke, Michelle J. ; Arnold, Paul M. ; Gokaslan, Ziya L. ; Fisher, Charles G. ; Laufer, Ilya ; the AO Spine Knowledge Forum Tumor</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4480-cfc36731370f13f84f9c4d940ff3a8fe779d75672eb805679fd055806bcef5a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Ablation</topic><topic>Aged</topic><topic>Bone cancer</topic><topic>Cancer</topic><topic>Demographics</topic><topic>Demography</topic><topic>Female</topic><topic>Health</topic><topic>Health services</topic><topic>health‐related quality of life (HRQOL)</topic><topic>Humans</topic><topic>International Cooperation</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical treatment</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>oligometastases</topic><topic>Oncology</topic><topic>Orthopedic Procedures</topic><topic>Patients</topic><topic>polymetastases</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Quality of life</topic><topic>Quality of Life - psychology</topic><topic>Questionnaires</topic><topic>Radiation therapy</topic><topic>Radiotherapy</topic><topic>Spinal cancer</topic><topic>Spinal Neoplasms - psychology</topic><topic>Spinal Neoplasms - secondary</topic><topic>Spinal Neoplasms - therapy</topic><topic>Spine</topic><topic>Surgery</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>tumor</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barzilai, Ori</creatorcontrib><creatorcontrib>Versteeg, Anne L.</creatorcontrib><creatorcontrib>Sahgal, Arjun</creatorcontrib><creatorcontrib>Rhines, Laurence D.</creatorcontrib><creatorcontrib>Bilsky, Mark H.</creatorcontrib><creatorcontrib>Sciubba, Daniel M.</creatorcontrib><creatorcontrib>Schuster, James M.</creatorcontrib><creatorcontrib>Weber, Michael H.</creatorcontrib><creatorcontrib>Pal Varga, Peter</creatorcontrib><creatorcontrib>Boriani, Stefano</creatorcontrib><creatorcontrib>Bettegowda, Chetan</creatorcontrib><creatorcontrib>Fehlings, Michael G.</creatorcontrib><creatorcontrib>Yamada, Yoshiya</creatorcontrib><creatorcontrib>Clarke, Michelle J.</creatorcontrib><creatorcontrib>Arnold, Paul M.</creatorcontrib><creatorcontrib>Gokaslan, Ziya L.</creatorcontrib><creatorcontrib>Fisher, Charles G.</creatorcontrib><creatorcontrib>Laufer, Ilya</creatorcontrib><creatorcontrib>the AO Spine Knowledge Forum Tumor</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barzilai, Ori</au><au>Versteeg, Anne L.</au><au>Sahgal, Arjun</au><au>Rhines, Laurence D.</au><au>Bilsky, Mark H.</au><au>Sciubba, Daniel M.</au><au>Schuster, James M.</au><au>Weber, Michael H.</au><au>Pal Varga, Peter</au><au>Boriani, Stefano</au><au>Bettegowda, Chetan</au><au>Fehlings, Michael G.</au><au>Yamada, Yoshiya</au><au>Clarke, Michelle J.</au><au>Arnold, Paul M.</au><au>Gokaslan, Ziya L.</au><au>Fisher, Charles G.</au><au>Laufer, Ilya</au><au>the AO Spine Knowledge Forum Tumor</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival, local control, and health‐related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>125</volume><issue>5</issue><spage>770</spage><epage>778</epage><pages>770-778</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>Background
The treatment of oligometastatic (≤5 metastases) spinal disease has trended toward ablative therapies, yet to the authors’ knowledge little is known regarding the prognosis of patients presenting with oligometastatic spinal disease and the value of this approach. The objective of the current study was to compare the survival and clinical outcomes of patients with cancer with oligometastatic spinal disease with those of patients with polymetastatic (>5 metastases) disease.
Methods
The current study was an international, multicenter, prospective study. Patients who were admitted to a participating spine center with a diagnosis of spinal metastases and who underwent surgical intervention and/or radiotherapy between August 2013 and May 2017 were included. Data collected included demographics, overall survival, local control, and treatment information including surgical, radiotherapy, and systemic therapy details. Health‐related quality of life (HRQOL) measures included the EuroQOL 5 dimensions 3‐level questionnaire (EQ‐5D‐3L), the 36‐Item Short Form Health Survey (SF‐36v2), and the Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ).
Results
Of the 393 patients included in the current study, 215 presented with oligometastatic disease and 178 presented with polymetastatic disease. A significant survival advantage of 90.1% versus 77.3% at 3 months and 77.0% versus 65.1% at 6 months from the time of treatment was found for patients presenting with oligometastatic disease compared with those with polymetastatic disease. It is important to note that both groups experienced significant improvements in multiple HRQOL measures at 6 months after treatment, with no differences in these outcome measures noted between the 2 groups.
Conclusions
The treatment of oligometastatic disease appears to offer a significant survival advantage compared with polymetastatic disease, regardless of treatment choice. HRQOL measures were found to improve in both groups, demonstrating a palliative benefit for all treated patients.
There appears to be a significant survival advantage for patients presenting with oligometastatic disease compared with those with polymetastatic disease at the time of the initial treatment of spinal metastases regardless of the treatment method used. In the current study, both groups are reported to experience significant improvements in multiple measures of health‐related quality of life at 6 months.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>30489634</pmid><doi>10.1002/cncr.31870</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-4037-8716</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2019-03, Vol.125 (5), p.770-778 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8020734 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; Alma/SFX Local Collection |
| subjects | Ablation Aged Bone cancer Cancer Demographics Demography Female Health Health services health‐related quality of life (HRQOL) Humans International Cooperation Male Medical prognosis Medical treatment Metastases Metastasis Middle Aged Neoplasm Metastasis oligometastases Oncology Orthopedic Procedures Patients polymetastases Prognosis Prospective Studies Quality of life Quality of Life - psychology Questionnaires Radiation therapy Radiotherapy Spinal cancer Spinal Neoplasms - psychology Spinal Neoplasms - secondary Spinal Neoplasms - therapy Spine Surgery Survival Survival Analysis Treatment Outcome tumor Tumors |
| title | Survival, local control, and health‐related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T17%3A36%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival,%20local%20control,%20and%20health%E2%80%90related%20quality%20of%20life%20in%20patients%20with%20oligometastatic%20and%20polymetastatic%20spinal%20tumors:%20A%20multicenter,%20international%20study&rft.jtitle=Cancer&rft.au=Barzilai,%20Ori&rft.date=2019-03-01&rft.volume=125&rft.issue=5&rft.spage=770&rft.epage=778&rft.pages=770-778&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/cncr.31870&rft_dat=%3Cproquest_pubme%3E2182192019%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2182192019&rft_id=info:pmid/30489634&rfr_iscdi=true |